title: Liver-specific imaging with SHU 563A: diagnostic potential of a new class of ultrasound contrast media.
abstract: The purpose of this study was to evaluate the imaging properties and diagnostic potential of the novel polymeric ultrasound contrast agent SHU 563 A. After i. v. injection, the agent circulates in the blood pool for about 10 min and is then subsequently sequestered by the RES cells predominantly in the liver. The acoustic emission capabilities enable a very sensitive detection during the blood pool phase and after uptake in the RES cells, contributing to differential diagnosis as well as detection of liver lesions. During a multicenter study, 28 patients with liver lesions were examined. In all patients the results were compared to baseline ultrasound and Contrast enhanced Spiral CT. With respect to lesion size and location, very good agreement between SHU 563 A ultrasound and Spiral CT was achieved. Additional lesions could be shown in the RES phase by SHU 563 A enhanced ultrasound. 26 further patients were examined in other indications. The results in all 54 patients indicate good safety and tolerance of SHU 563 without limitations for diagnostic use. SHU 563 A enhanced ultrasound adds significantly to the detection and delineation of focal liver lesions by improving conspicuity due to RES based contrast after uptake.
authors.affiliation: Clinical Development Ultrasound Contrast Media, Schering AG, D-13342 Berlin, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Bauer
authors.forename: M
authors.initials: M
authors.lastname: Blomley
authors.forename: E
authors.initials: E
authors.lastname: Leen
authors.forename: D
authors.initials: D
authors.lastname: Cosgrove
authors.forename: R
authors.initials: R
authors.lastname: Schlief
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000503:physiopathology / Q000556:secondary; D001706:Biopsy; D001783:Blood Flow Velocity; D003287:Contrast Media; D003937:Diagnosis, Differential; D004659:Enbucrilate / Q000008:administration & dosage; D006801:Humans; D007275:Injections, Intravenous; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000503:physiopathology / Q000556:secondary; D009382:Neoplasms, Unknown Primary / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology; D011108:Polymers; D012449:Safety; D012680:Sensitivity and Specificity; D018615:Ultrasonography, Doppler, Color / Q000379:methods*
chemical_list: D003287:Contrast Media; D011108:Polymers; C105825:SH U 563 A; D004659:Enbucrilate